Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043 Orbassano, Turin, Italy.
BMC Cancer. 2018 Apr 26;18(1):470. doi: 10.1186/s12885-018-4395-5.
Adenocarcinomas of the oral cavity are rare neoplasms, and only four cases of primary colonic adenocarcinoma of the tongue have ever been described in literature. Very few information about chemotherapy sensitiveness of this type of neoplasia is available, with only one regimen that showed some activity in a metastatic patient.
We describe the case of a patient bearing a metastatic colonic adenocarcinoma of the tongue submitted to a first-line chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid (FOLFOX regimen). After chemotherapy the patient obtained the complete disappearance of the primitive neoplasia located in the body of the tongue, and a tumor size reduction > 50% of liver and lung metastases.
This case demonstrated the activity of the combination of oxaliplatin and 5-fluorouracil in this very rare neoplasia. The FOLFOX regimen might be considered either in advanced and especially in the neoadjuvant setting, when the reduction of the primary tumor is highly needed.
口腔腺癌是罕见的肿瘤，文献中仅描述过 4 例原发性结直肠舌腺癌。对于这种类型的肿瘤，关于化疗敏感性的信息非常有限，只有一种方案在转移性患者中显示出一定的活性。
我们描述了一例转移性结直肠舌腺癌患者，该患者接受了一线化疗，包括奥沙利铂、5-氟尿嘧啶和亚叶酸钙（FOLFOX 方案）。化疗后，患者舌体原发肿瘤完全消失，肝脏和肺部转移瘤的大小减少>50%。
该病例表明奥沙利铂和 5-氟尿嘧啶联合应用于这种非常罕见的肿瘤具有活性。FOLFOX 方案可考虑用于晚期肿瘤，特别是在需要降低原发肿瘤大小的新辅助治疗中。
